wilate 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii - von willebrand disease (vwd) :prevention and treatment of haemorrhage or surgical bleeding in von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or contra-indicated.haemophilia a :treatment and prophylaxis of bleeding in patients with haemophilia a (congenital fviii deficiency).
wilate 500
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii - von willebrand disease (vwd) :prevention and treatment of haemorrhage or surgical bleeding in von willebrand disease (vwd), when desmopressin (ddavp) treatment alone is ineffective or contra-indicated.haemophilia a :treatment and prophylaxis of bleeding in patients with haemophilia a (congenital fviii deficiency).
optivate 500 i.u
kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).
optivate 1000 i.u
kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).
dried factor viii fraction, type 8y
bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - factor viii, human - powder and solvent for solution for injection - factor viii, human 25 iu/ml - antihemorrhagics
haemate p 1000iu powder and solvent for solution for injection or infusion
dksh malaysia sdn. bhd. - human coagulation factor viii; von willebrand factor -
haemoctin sdh 250 iu
kamada ltd, israel - human plasma coagulation factor viii - powder for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.
haemoctin sdh 500 iu
kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.
haemoctin sdh 1000 iu
kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.
wilate 500,500 iu fviii/500 iu vwf inj. sol. (pwdr. + solv.) i.v. vial
octapharma benelux sa-nv - human factor von willebrand 500 iu; human coagulation factor viii 500 iu - powder and solvent for solution for injection - factor von willebrand 100 iu/ml; human coagulation factor viii 100 iu/ml - von willebrand factor and coagulation factor viii in combination